SCHEMBL17282019

SCHEMBL17282019

CN(Cc1cccc(Br)c1)C1CCN(C(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ RIPK1 Q13546 1/20 0.43
▸ NOS3 P29474 2/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ NOS2 P35228 2/20 0.43
▸ PYCR1 P32322 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.40
▸ MBTD1 Q05BQ5 1/20 0.39
▸ L3MBTL3 Q96JM7 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ SLC6A2 P23975 2/20 0.37
▸ SLC6A4 P31645 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17286027 0.85 KDM4E (0.59) SIGMAR1KDM4EALDH1A1NOS3NOS1
SCHEMBL22878388 0.85 SIGMAR1 (0.49) SIGMAR1KDM4EALDH1A1RIPK1NOS3
SCHEMBL17284490 0.84 SIGMAR1 (0.48) SIGMAR1KDM4EALDH1A1RIPK1NOS3
SCHEMBL17282142 0.83 HRH3 (0.46) KDM4EALDH1A1NOS3NOS1NOS2
SCHEMBL13050349 0.83 GRIN2B (0.49) SIGMAR1KDM4EALDH1A1NOS3NOS1
SCHEMBL17282009 0.83 UBE2M (0.48) KDM4EALDH1A1SLC6A2SLC6A4MAOB
SCHEMBL17282146 0.80 SLC6A2 (0.59) SIGMAR1PYCR1SLC6A2SLC6A4SLC6A3
SCHEMBL17282102 0.80 NOS3 (0.43) KDM4EALDH1A1NOS3NOS1NOS2
SCHEMBL17282022 0.77 SIGMAR1 (0.53) SIGMAR1ALDH1A1NOS3NOS1NOS2
SCHEMBL17282144 0.75 NOS3 (0.47) KDM4EALDH1A1NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145020-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-05-25 — — US disclosed
US-9604984-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2017-03-28 — — US disclosed
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-18 — — US disclosed
US-9346815-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2016-05-24 — — US disclosed
US-20150336962-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-11-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336962-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 SIGMAR1 1418/4885KDM4E 708/4885ALDH1A1 729/4885
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 SIGMAR1 1418/4885KDM4E 708/4885ALDH1A1 729/4885
US-20170145020-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 SIGMAR1 1418/4885KDM4E 708/4885ALDH1A1 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback